Michael L. Whitfield
YOU?
Author Swipe
View article: Multimodal Analyses of Early, Untreated SSc Skin Identify a Proinflammatory Vascular Niche of Macrophage-Fibroblast Signaling
Multimodal Analyses of Early, Untreated SSc Skin Identify a Proinflammatory Vascular Niche of Macrophage-Fibroblast Signaling Open
Uncovering the early interactions and spatial distribution of dermal fibroblasts and immune cells in treatment-naïve diffuse cutaneous systemic sclerosis (dcSSc) patients is critical to understanding the earliest events of skin fibrosis. W…
View article: RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosis
RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosis Open
This study is the first to demonstrate a potential role for RUNX1 in the pathogenesis of SSc dermal fibrosis. RUNX1 is associated with more severe SSc fibrosis and is associated with a subpopulation of dermal fibroblasts implicated in fibr…
View article: Using chimeric antigen receptor (CAR) T Cells to autoimmune systemic sclerosis (SSc) 4232
Using chimeric antigen receptor (CAR) T Cells to autoimmune systemic sclerosis (SSc) 4232 Open
Description Macrophages (MØs) are implicated in the pathogenesis of systemic sclerosis (SSc), an inflammatory and fibrotic autoimmune disease. Our prior work has shown that MØs from SSc patients secrete elevated levels of TGF-b and CCL2, h…
View article: Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue
Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue Open
Fibrosis drives pathology in the chronic autoimmune disease systemic sclerosis (SSc), which has the highest case fatality rate of any systemic autoimmune disease with no validated biomarkers or curative treatments. Our prior work has shown…
View article: Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody
Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody Open
Immune-driven fibrotic skin diseases, including scleroderma/systemic sclerosis (SSc) and chronic graft-versus-host disease (GVHD), cause skin stiffening that has a major impact on patient quality of life and associated patient mortality. T…
View article: Mycophenolate mofetil directly modulates myeloid viability and pro-fibrotic activation of human macrophages
Mycophenolate mofetil directly modulates myeloid viability and pro-fibrotic activation of human macrophages Open
Objectives Mycophenolate mofetil (MMF) is an immunosuppressant used to treat rheumatological diseases, including systemic sclerosis (SSc). While MMF is an established inhibitor of lymphocyte proliferation, recent evidence suggests MMF also…
View article: RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis
RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis Open
The activation of Runt-related transcription factor 1 (RUNX1) in fibroblasts has been implicated in wound healing and fibrosis; however, the role of RUNX1 in the fibrotic progression of the autoimmune disease systemic sclerosis (SSc) is no…
View article: Single-cell epigenomic dysregulation of Systemic Sclerosis fibroblasts via CREB1/EGR1 axis in self-assembled human skin equivalents
Single-cell epigenomic dysregulation of Systemic Sclerosis fibroblasts via CREB1/EGR1 axis in self-assembled human skin equivalents Open
Systemic sclerosis (SSc) is an autoimmune disease characterized by skin fibrosis, internal organ involvement and vascular dropout. We previously developed and phenotypically characterized an in vitro 3D skin-like tissue model of SSc, and n…
View article: CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant Melanoma
CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant Melanoma Open
Approximately 50% of advanced melanomas harbor activating BRAF V600E mutations that are sensitive to BRAF inhibition. However, the duration of the response to BRAF inhibitors (BRAFi) has been limited due to the development of acquired resi…
View article: Supplementary Figure S6 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S6 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Tumor growth in mice treated with BRAFi +/- MDSC depletion.
View article: Supplementary Methods and References from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Methods and References from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Description of additional methods and procedures used in the study. Also includes Supplementary References.
View article: Data from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Data from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Acquired resistance to BRAFV600E inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nature of cancers. Although there has been significant…
View article: Supplementary Figure S5 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S5 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Depletion of intratumoral MDSC.
View article: Supplementary Figure S3 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S3 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Heat maps depicting individual gene expression changes following extended BRAFi treatment in individual mice.
View article: Data from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Data from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Acquired resistance to BRAFV600E inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nature of cancers. Although there has been significant…
View article: Supplementary Figure S3 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S3 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Heat maps depicting individual gene expression changes following extended BRAFi treatment in individual mice.
View article: Supplementary Methods and References from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Methods and References from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Description of additional methods and procedures used in the study. Also includes Supplementary References.
View article: Supplementary Figure S1 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S1 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Flow cytometry gating strategies.
View article: Supplementary Figure S4 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S4 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Effects of the CCR2/CCL2 axis on intratumoral MDSC populations and tumor growth.
View article: Supplementary Figure S1 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S1 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Flow cytometry gating strategies.
View article: Supplementary Figure S2 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S2 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Tumor size comparisons between group.
View article: Supplementary Figure S5 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S5 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Depletion of intratumoral MDSC.
View article: Supplementary Figure S7 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S7 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
BRAFi responsiveness and resistance kinetics in RAG -/- and CD8 -/- versus wild-type mice.
View article: Supplementary Figure S7 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S7 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
BRAFi responsiveness and resistance kinetics in RAG -/- and CD8 -/- versus wild-type mice.
View article: Supplementary Figure S4 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S4 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Effects of the CCR2/CCL2 axis on intratumoral MDSC populations and tumor growth.
View article: Supplementary Figure S2 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S2 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Tumor size comparisons between group.
View article: Supplementary Figure S6 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Supplementary Figure S6 from Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Open
Tumor growth in mice treated with BRAFi +/- MDSC depletion.
View article: Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation
Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation Open
Here, the efficacy of abatacept in patients with early diffuse systemic sclerosis (dcSSc) was analyzed to test the hypothesis that patients in the inflammatory intrinsic subset would show the most significant clinical improvement. Eighty-f…